Short-course fluoroquinolone treatment is as effective as the conventional 7-day course for acute exacerbations of chronic ...

According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of ...

As per the agreement, SUP will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the ...

Mumbai: Global pharma major Lupin Limited has signed a supply and license agreement with Sino Universal Pharmaceuticals (SUP) ...

Lupin partners with SUP to commercialize Tiotropium DPI in China for COPD treatment, expanding respiratory care options.

Lupin & Sino Universal Pharmaceuticals ink license and supply agreement for tiotropium DPI in China: Our Bureau, Mumbai Monday, June 16, 2025, 14:30 Hrs [IST] Global pharma major ...

Under the terms of the agreement, SUP will be responsible for obtaining the necessary regulatory approvals to sell Tiotropium ...

New Partnership with Leonard Nimoy’s Daughter Aims to Raise COPD Awareness ...

A 6-minute walk of less than 350 meters tripled the mortality risk, whereas chronic kidney disease (CKD) independently ...

The following is a summary of “Triple overlap of COPD, severe obesity, and high risk of OSA: insights from an NHANES analysis ...

Since the pandemic, the number of working days lost to respiratory conditions has more than doubled. Now accounting for 8.7 ...